Key result
TAVR is associated with no 30-day deaths vs SAVR and better perioperative metrics in lower-risk patients.
Why the study?
While TAVR is established for high-risk aortic regurgitation patients, its applicability to low- and intermediate-risk populations remains under investigation.
Does transcatheter aortic valve replacement improve short-term clinical outcomes compared to surgical aortic valve replacement in low- to intermediate-risk patients with aortic regurgitation?
Population
70 low- to intermediate-risk AR patients
Comparison
TAVR vs SAVR with bioprosthetic valves
Design
Single-center retrospective study
Follow-up
30 days
Authors
Loading...
May support TAVR in low-to-intermediate-risk AR; extends observational evidence but leaves open causality pending RCTs.
Does transcatheter aortic valve replacement improve short-term clinical outcomes compared to surgical aortic valve replacement in low- to intermediate-risk patients with aortic regurgitation?
TAVR may offer favorable short-term outcomes, including lower 30-day mortality and shorter hospital stays, compared to SAVR in low- to intermediate-risk patients with aortic regurgitation.
Zhang et al. (2026) studied this question. TAVR resulted in zero 30-day mortality versus four deaths with SAVR (p=0.029) and significantly reduced operation time, blood use, and hospital stays in low- to intermediate-risk patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: